# US 2023/0265195 A1 · Target-recognition of antigen-mhc complex reporter (tracer) platform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265195 A1
- Document ID: US20230265195A1
- Status: Published application
- Kind: A1
- Application number: 18/016,243
- Filed: 2021-07-30
- Published: 2023-08-24
- Earliest claimed: 2020-07-31
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Possu Huang; Haotian Du
- Web page: https://patentgrep.com/patent/US20230265195A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61K 39/001188: {NY-ESO}
- A61K 39/12: Viral antigens
- C07K 14/30: from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Abstract: Compositions and methods are provided relating to the design, screening and therapeutic use of designed binding proteins that specifically interact with an MHC/peptide complex. Proteins that specifically bind to an MHC/antigenic peptide complex of interest are designed through engineering of protein structure and screening assays. Selected binders are screened to minimize cross-reactivity with self-MHC-peptides. The antigen binding region thus developed can be formatted into a therapeutic agent that activates cytolytic pathways.

## Claims

### Claim 1

A population of polypeptides comprising a sequence characterized as:
at least 85% sequence identity to SEQ ID NO:1, residues 1-124;
comprising a randomized region of from 1 to 10 amino acids within residues 12 and 22;
comprising two cysteine residues that form a disulfide bond;
wherein a polypeptide in the population binds to a Class II MHC protein with an affinity of less than 106M.

### Claim 2

A population of polypeptides comprising an amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4, wherein a polypeptide in the population binds to a Class II MHC protein with an affinity of less than 10-6M, optionally wherein the population comprises at least 106 different sequences.

### Claim 3 (depends on 1)

A population of polypeptides of claim 1, comprising the amino acid sequence of SEQ ID NO:4, optionally where the MHC Class II protein is HLA DR1.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 2)

A polypeptide selected from the population of claim 2, comprising an amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, wherein the polypeptide binds to an MHC Class II/peptide complex at an affinity of less than 10-6M, optionally wherein the peptide in the complex is a peptide of a pathogen antigen, a cancer-associated antigen, or an auto-antigen.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The polypeptide of claim 6, wherein the polypeptide is fused to an immune effector polypeptide, wherein the effector polypeptide is an Fc sequence, a chimeric antigen receptor, or a CD3-based bispecific T-cell engager.

### Claim 9

(canceled)

### Claim 10 (depends on 2)

A population of polypeptides according to claim 2, comprising a sequence as set forth in SEQ ID NO:5:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
M
K
L
R
C
E
N
P
K
K
A
X
X
X
N
X
Q
N
L
N
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
N
V
V
F
T
N
K
E
L
E
D
I
Y
D
L
S
N
K
E
E
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
T
K
E
V
L
K
L
F
K
L
K
V
N
Q
F
Y
R
H
A
F
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
G
I
V
N
D
Y
G
D
K
E
I
F
N
M
M
F
X
X
L
W
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
X
V
F
X
S
Q
X
X
X
A
N
N
V
E
X
I
K
X
N
I
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
X
X
L
D
W
I
M
A
E
A
D
N
D
L
C
Y
F
I
S
Q
where X is any amino acid.

### Claim 11 (depends on 10)

A population of polypeptides according to claim 10, comprising a sequence as set forth in SEQ ID NO:5, comprising one or more randomized residues as follows:
residue 9 is selected from K/D/V
residue 10 is selected from K/E/H
residue 12 is any amino acid other than C
residue 13 is any amino acid other than C
residue 14 is any amino acid other than C
residue 15 is selected from N/D/F/R
residue 16 is selected from A/L/M
residue 19 is selected from L/E/F/N/Q/W/Y
residue 22 is selected from V/L
residue 77 is selected from E/L/M/A/I/N/W
residue 78 is selected from L/M/F
residue 80 is selected from W/F/I/K/L/Y
residue 81 is selected from A/E/I/L/M/Q/S/T/V/W/Y
residue 82 is selected from D/I/L/M/Q/R/S/T/V/W
residue 85 is selected from S/I/L/M/T
residue 87 is selected from R/W/H/K/M/T
residue 88 is selected from F/Y/I/L/R/V/W
residue 89 is selected from N/S/A/F/W/Y
residue 92 is selected from D/N
residue 95 is selected from L/M/Q/V
residue 97 is selected from K/E
residue 98 is selected from F/A/L/T/W
residue 101 is selected from K/R/E/F
residue 102 is selected from M/F/I/L/T/V
residue 105 is selected from W/F/L/M
residue 108 is selected from A/K/R
residue 109 is selected from E/F/K/M/Q/V.

### Claim 12 (depends on 10)

A population of polypeptides according to claim 10, comprising an amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6, wherein a polypeptide in the population binds to a Class I MHC protein with an affinity of less than 106M, optionally wherein the MHC Class I protein is an HLA-A*02 allele, optionally wherein the population comprises at least 106 different sequences.

### Claim at position 12

13-14. (canceled)

### Claim 15 (depends on 12)

A polypeptide selected from the population of claim 12 comprising an amino acid of SEQ ID NO:6, wherein the polypeptide binds to an MHC Class I/peptide complex at an affinity of less than 10-6M, optionally wherein the peptide in the complex is a peptide of a pathogen antigen, a cancer-associated antigen, or an auto-antigen.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The polypeptide of claim 15, wherein the polypeptide is fused to an immune effector polypeptide, wherein the effector polypeptide is an Fc sequence, a chimeric antigen receptor, or a CD3-based bispecific T-cell engager.

### Claim 18

(canceled)

### Claim 19

A polypeptide comprising a sequence according to any of SEQ ID NO:10, 11, 12, 13 or 16.

### Claim 20 (depends on 2)

A polypeptide selected from the population of claim 2, comprising a sequence according to SEQ ID NO:3, wherein residues 12-16 comprise a sequence selected from any of SEQ ID NO:17-SEQ ID NO:40.

### Claim at position 19

21-33. (canceled)
